The epidermal growth factor receptor (EGFR) has been broadly explored as a drug target for treatment, since it is overexpressed in various tumors, such as breast and lung carcinomas (Kim et al., 2001; Camp et al., 2005). This evidence concerns the gene EGFR and lung carcinoma.